ストックスクリーナーアプリを入手
32.49
0.95%
-0.31
アフターアワーズ：
32.49
前日終値:
$32.80
開ける：
$32.61
24時間の取引高:
1.84M
Relative Volume:
0.76
時価総額：
$4.19B
収益：
-
当期純損益:
$-507.65M
株価収益率:
-7.063
EPS:
-4.6
ネットキャッシュフロー:
$-616.24M
1週間 パフォーマンス:
-0.15%
1か月 パフォーマンス:
-6.56%
6か月 パフォーマンス:
-65.56%
1年 パフォーマンス:
-53.72%
1日の値動き範囲:
$31.37
$33.15
1週間の範囲:
$31.07
$33.30
52週間の値動き範囲:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
名前
Vaxcyte Inc
セクター
電話
650-837-0111
住所
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
PCVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
32.49 | 4.20B | 0 | -507.65M | -616.24M | -4.60 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 開始されました | Goldman | Buy |
| 2023-12-07 | 開始されました | Mizuho | Buy |
| 2023-04-18 | 開始されました | TD Cowen | Outperform |
| 2023-01-03 | 繰り返されました | Needham | Buy |
| 2022-12-15 | 開始されました | Guggenheim | Buy |
| 2022-11-17 | 開始されました | BTIG Research | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-24 | 再開されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | BofA Securities | Buy |
| 2020-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 開始されました | Needham | Buy |
すべてを表示
Vaxcyte Inc (PCVX) 最新ニュース
Vaxcyte (VCYT) Jumps Over 4.5%: Is This Biotech Eyeing a Return Towards Its $121 High? - Daily Chhattisgarh News
Here’s Why Vaxcyte (PCVX) Sold Off in Q1 - Insider Monkey
How the (PCVX) price action is used to our Advantage - news.stocktradersdaily.com
James T. Wassil ’99G ’05G of Vaxcyte Inc., Tells Graduates ‘The Journey Ahead is Yours to Shape’ - Lehigh University
Transcript : Vaxcyte, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? - MSN
Vaxcyte, Inc. Reports Q1 2025 Financial Results - TipRanks
11 Stocks That Will Bounce Back According to Analysts - Insider Monkey
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight - GuruFocus
Vaxcyte (PCVX) Advances Pneumococcal Vaccine Development | PCVX Stock News - GuruFocus
Vaxcyte Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Vaxcyte Inc Reports Q1 2025 EPS of -$1.04, Beating Estimates; Net Loss Widens to $140.7 Million - GuruFocus
Oversold Conditions For Vaxcyte (PCVX) - Nasdaq
Vaxcyte (PCVX) Stock Price, News & Analysis - MarketBeat
Vaxcyte appoints new independent director - Investing.com Australia
Vaxcyte appoints new independent director By Investing.com - Investing.com South Africa
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte (PCVX) Welcomes Former Sanofi CEO to Board of Directors - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board - TipRanks
Vaxcyte adds former Sanofi CEO to its board - Investing.com
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors | PCVX Stock News - GuruFocus
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors - The Manila Times
Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? - Yahoo Finance
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
PCVXVaxcyte, Inc. Latest Stock News & Market Updates - Stock Titan
James T. Wassil ’99G ’05G of Vaxcyte, Inc. Named Lehigh’s 2025 Graduate Commencement and Doctoral Hooding Ceremony Speaker - Lehigh University
Vaxcyte (PCVX) Gains Attention with Overweight Rating Amid Marke - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz - GuruFocus
Vaxcyte (PCVX) Sees Surge in Investor Interest Amid Biotech Buzz | PCVX Stock News - GuruFocus
Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options - Nasdaq
TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX) - The Globe and Mail
When the Price of (PCVX) Talks, People Listen - news.stocktradersdaily.com
2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340% - The Globe and Mail
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason - MSN
Vaxcyte Stock Plummets: What’s Next? - timothysykes.com
Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential - Insider Monkey
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges - Investing.com India
Vaxcyte stock plunges to 52-week low at $29.53 amid market challenges By Investing.com - Investing.com South Africa
Vaxcyte Inc (PCVX) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):